Sawai Singh Rathore

Sawai Singh Rathore

Auto-generated profile, based on publicly available information

Sawai Singh Rathore

Department of Internal Medicine, Dr. Sampurnanand Medical College, Jodhpur, Rajasthan, India

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2021 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
PDF file
SRSawai Singh Rathore
Sawai Singh Rathore
GRGianpier Alonzo Rojas
Gianpier Alonzo Rojas
MSManush Sondhi
Manush Sondhi
SPSuveenkrishna Pothuru
Suveenkrishna Pothuru
RPReshma Pydi
Reshma Pydi
QWQingqing Wen
Qingqing Wen

28 December 2021 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
NHNabeel Hussain
Nabeel Hussain
PAPreeti Agarwala
Preeti Agarwala
KIKinza Iqbal
Kinza Iqbal
HOHanaa Mohamed Sheikh Omar
Hanaa Mohamed Sheikh Omar
GJGurusha Jangid
Gurusha Jangid
NANoman Khurshid Ahmed
Noman Khurshid Ahmed

27 August 2022 in Reviews in Medical Virology
Verified
Journal Article
Closed access
SRSawai Singh Rathore
Sawai Singh Rathore
SOSharvi Oberoi
Sharvi Oberoi
KIKinza Iqbal
Kinza Iqbal
KBKeshav Bhattar
Keshav Bhattar
GBGuadalupe Abigail Benítez‐López
Guadalupe Abigail Benítez‐López
KKKhalil Khalil
Khalil Khalil

1 September 2021 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
SRSawai Singh Rathore
Sawai Singh Rathore
NHNabeel Hussain
Nabeel Hussain
AMAde Harrison Manju
Ade Harrison Manju
QWQingqing Wen
Qingqing Wen
STSohaib Tousif
Sohaib Tousif
DPDeep Manojkumar Patel
Deep Manojkumar Patel
Observational studies indicate that pleural effusion has an association with risk and the clinical prognosis of COVID‐19 disease; however, the available literature on this area is inconsistent. The objective of this systematic review and meta‐analysis is to evaluate the correlation between COVID‐19 disease and pleural effusion. A rigorous literature search was conducted using multiple databases. All eligible observational studies were included from around the globe. The pooled prevalence and associated 95% confidence interval (CI) were calculated using the random effect model. Mantel–Haenszel odds ratios were produced to report overall effect size using random effect models for severity and mortality outcomes. Funnel plots, Egger regression tests, and Begg–Mazumdar's rank correlation test were used to appraise publication bias. Data from 23 studies including 6234 COVID‐19 patients was obtained. The overall prevalence of pleural effusion in COVID‐19 patients was 9.55% (95% CI,I2 = 92%). Our findings also indicated that the presence of pleural effusions associated with increased risk of severity of disease(OR = 5.08, 95% CI 3.14–8.22,I2 = 77.4%) and mortality due to illness(OR = 4.53, 95% CI 2.16–9.49,I2 = 66%) compared with patients without pleural effusion. Sensitivity analyses illustrated a similar effect size while decreasing the heterogeneity. No significant publication bias was evident in the meta‐analysis. The presence of pleural effusion can assist as a prognostic factor to evaluate the risk of worse outcomes in COVID‐19 patients hence, it is recommended that hospitalized COVID‐19 patients with pleural effusion should be managed on an early basis.

15 March 2021 in Cureus
Verified
Journal Article
Open access
TMTrishala Menon
Trishala Menon
RSRohit Sharma
Rohit Sharma
Saurabh KatariaSaurabh Kataria
Saurabh Kataria
SSSundus Sardar
Sundus Sardar
RARamesh Adhikari
Ramesh Adhikari
ZAZahoor Ahmed
Zahoor Ahmed
The coronavirus disease 2019 (COVID-19) pandemic has become a global healthcare emergency. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, has a wide range of clinical manifestations ranging from subclinical infection to multi-organ failure. In addition to the respiratory system, COVID-19 also adversely affects the kidneys. In this study, we aimed to measure the prevalence of acute kidney injury (AKI) in COVID-19 and its association with the disease severity and mortality in COVID-19 patients. We conducted our study by following the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) guidelines. A comprehensive literature search using four databases (PubMed, EMBASE, Google Scholar, and clinicaltrial.gov) was performed. Our initial search returned 2,771 articles. After excluding review articles, duplicates, and non-relevant studies, we included 20 articles that reported an association between COVID-19 and AKI. We subsequently performed a random effect analysis to find the pooled prevalence, pooled odds ratio (OR) estimates, and 95% confidence intervals for severe COVID-19 and mortality outcomes in AKI using Cochrane RevMan (version 5.4) and R programming language (version 4.16-2). A total of 14,415 patients from various countries were included. Among the 20 cohorts, the median age was 55.8 ±8.39 years (range: 43-72 years), and 43.78% of the subjects were female. Out of a total of 14,415 patients, 3,820 developed AKI with a pooled prevalence of 11% (95% CI: 0.07-0.15; p<0.01; I2=98%). AKI was found to have a significant association with severe COVID-19 disease, with a pooled OR of 8.45 (95% CI: 5.56-12.56; p<0.00001; I2=0%). AKI was associated with significantly higher mortality in patients with COVID-19 with an OR of 13.52 (95% CI: 5.43-33.67; p<0.00001; I2=88%). AKI manifests as a common COVID-19 complication, and COVID-19 patients with AKI generally have poor outcomes in terms of disease severity and mortality.

12 February 2021 in Cureus
Verified
Journal Article
Open access
PDF file
TMTrishala Menon
Trishala Menon
RSRohit Sharma
Rohit Sharma
GEGeethika Earthineni
Geethika Earthineni
HIHanan Iftikhar
Hanan Iftikhar
MSManush Sondhi
Manush Sondhi
RSRomil Singh
Romil Singh
At present, the novel coronavirus disease (COVID-19) is causing a major pandemic. COVID-19 is caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). In COVID-19, the patient usually presents with fever, dry cough, and respiratory manifestations. However, the involvement of other systems has also been reported in the literature. Abdominal pain, diarrhea, vomiting, and nausea are the predominant gastrointestinal (GI) manifestations underlined in the literature. We conducted a literature search using four databases (PubMed, Web of Science, Google Scholar, and Clinicaltrials.gov). Our search strategy included Medical Subject Headings (MeSH) terms and keywords for COVID-19, SARS-CoV-2, and GI system from inception to October 2020. After excluding duplicates, review articles, and non-relevant articles, we included 20 studies out of 842 articles reporting GI manifestations in COVID-19 patients. Using Cochrane RevMan version 5.4 (Cochrane, London, UK), a compute pooled analysis using a random-effect model was performed. Our study included 6,022 patients with a median age of 49.5 years. Pooled analysis via random effect model revealed an increased risk of severe COVID-19 in patients manifesting GI symptoms with an odds ratio (OR) of 2.07 (95% Confidence Interval [CI]: 1.34-3.18) with I2=41%). Odds of mortality in COVID-19 with GI manifestation and hepatic abnormalities included 0.92 (95% CI: 0.50-1.69) (I2=57%) and 1.26 (95% CI: 0.67-2.37) (I2=0%), respectively. Severe COVID-19 may have a strong association with GI manifestations and have a significant impact on GI practice. Holistic knowledge of the spectrum of the GI consequences in COVID-19 is crucial to get a hold of virus spread. In this article, we have summarized the association of GI manifestations in severe COVID-19 patients.